title: Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms.
abstract: This article reviews the use of aberrant antigen expression detected by flow cytometry in the diagnosis and clinical handling of acute myeloid leukaemia (AML) and the myelodysplastic syndromes (MDS). Such aberrancies offer a valuable tool for the proper classification of these myeloid malignancies according the World Health Organization 2008 classification. Aberrant antigen expression by flow cytometry is also important for prognostification. This review supports the view, that minimal residual disease detection methods that make use of such aberrancies should be part of the routine management of AML patients to guide therapy, but also suggests the introduction of flow cytometry in MDS for diagnosis and treatment decisions in the near future.
authors.affiliation: Department of Haematology, VU University Medical Center, De Boelelaan 1117, Amsterdam, the Netherlands. g.ossenkoppele@vumc.nl
authors.forename: Gert J
authors.initials: GJ
authors.lastname: Ossenkoppele
authors.forename: Arjan A
authors.initials: AA
authors.lastname: van de Loosdrecht
authors.forename: Gerrit Jan
authors.initials: GJ
authors.lastname: Schuurhuis
mesh_terms: D000951:Antigens, Neoplasm / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy; D009190:Myelodysplastic Syndromes / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy; D018365:Neoplasm, Residual; D014411:Neoplastic Stem Cells / Q000473:pathology; D011379:Prognosis
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor